https://www.biopharmawatch.com/news/BYSI/beyondspring-reports-q2-2026-results-and-update BiopharmaWatch en 2026-08-14T21:15:00.000Z BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/RVP/retractable-technologies-q2-2026-results BiopharmaWatch en 2026-08-14T21:12:00.000Z Retractable Technologies, Inc. Results for the Periods Ended June 30, 2026 https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-actimab-a-advances-nyse-update BiopharmaWatch en 2026-08-14T21:02:00.000Z Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update https://www.biopharmawatch.com/news/SLN/silence-therapeutics-upsized-public-offering BiopharmaWatch en 2026-08-14T20:55:00.000Z Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs https://www.biopharmawatch.com/news/OPTH/optimi-health-discretionary-equity-facility BiopharmaWatch en 2026-08-14T20:55:00.000Z Optimi Health Establishes Discretionary Equity Facility https://www.biopharmawatch.com/news/CTOR/citius-oncology-fiscal-q3-2026-results BiopharmaWatch en 2026-08-14T20:30:00.000Z Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-fiscal-third-quarter-2026-update BiopharmaWatch en 2026-08-14T20:30:00.000Z Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PROF/profound-medical-announces-management-change BiopharmaWatch en 2026-08-14T20:30:00.000Z Profound Medical Announces Management Change https://www.biopharmawatch.com/news/TRAW/traws-pharma-q2-2026-financial-results-business-highlights BiopharmaWatch en 2026-08-14T20:30:00.000Z Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-14T20:28:00.000Z Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update https://www.biopharmawatch.com/news/HSDT/solana-company-reports-q2-2026-results BiopharmaWatch en 2026-08-14T20:25:00.000Z Solana Company Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-q2-2026-financial-results-update BiopharmaWatch en 2026-08-14T20:05:00.000Z Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 https://www.biopharmawatch.com/news/CUE/cue-biopharma-q2-2026-financial-results BiopharmaWatch en 2026-08-14T20:05:00.000Z Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/LONA/leonabio-q2-2026-financial-results-business-update BiopharmaWatch en 2026-08-14T20:05:00.000Z LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/FEMY/femasys-financial-results-quarter-ended-june-30-2026 BiopharmaWatch en 2026-08-14T20:05:00.000Z Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update https://www.biopharmawatch.com/news/BSEM/biostem-technologies-sidoti-microcap-conference BiopharmaWatch en 2026-08-14T20:05:00.000Z BioStem Technologies to Present at the Sidoti MicroCap Conference https://www.biopharmawatch.com/news/PRPO/precipio-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-14T20:00:00.000Z Precipio Announces Q2-2026 Financial Results https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-14T19:47:00.000Z 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/HCWB/hcw-biologics-q2-2026-highlights-results BiopharmaWatch en 2026-08-14T19:15:00.000Z HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results https://www.biopharmawatch.com/news/ENVB/fda-psychedelic-drug-development-envb BiopharmaWatch en 2026-08-14T18:37:30.000Z What The FDA’s Psychedelic Drug Focus Means For Classic Psychedelic Development [Clinical Leader] https://www.biopharmawatch.com/news/DARE/dare-bioscience-announces-6-million-offering BiopharmaWatch en 2026-08-14T16:45:00.000Z Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-4m-private-placement BiopharmaWatch en 2026-08-14T15:45:00.000Z WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-4m-private-placement BiopharmaWatch en 2026-08-14T15:07:00.000Z bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-14T15:00:09.000Z Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/SKYE/skye-redx-transaction-agreement-125-million-financing BiopharmaWatch en 2026-08-14T13:33:00.000Z Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings https://www.biopharmawatch.com/news/TRIB/trinity-biotech-secures-investment-nasdaq-compliance BiopharmaWatch en 2026-08-14T13:32:00.000Z Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/LFWD/lifeward-reports-strong-q2-2026-results BiopharmaWatch en 2026-08-14T13:15:00.000Z Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-14T12:45:00.000Z Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-phase-2-3-trial-update BiopharmaWatch en 2026-08-14T12:45:00.000Z Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/NMAD/nomad-power-solutions-files-2026-q2-form-10-q-update BiopharmaWatch en 2026-08-14T12:35:00.000Z NOMAD POWER SOLUTIONS FILES 2026 SECOND QUARTER FORM 10-Q, PROVIDES BUSINESS UPDATE https://www.biopharmawatch.com/news/PHGE/biomx-zorronet-300k-order-defense-technology BiopharmaWatch en 2026-08-14T12:32:00.000Z BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site https://www.biopharmawatch.com/news/CLNN/clene-reports-q2-2026-results-and-highlights BiopharmaWatch en 2026-08-14T12:30:00.000Z Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-miracle-trial-update BiopharmaWatch en 2026-08-14T12:30:00.000Z Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-corporate-update-q2-2026 BiopharmaWatch en 2026-08-14T12:30:00.000Z Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SCNX/scienture-reports-q2-2026-results-revenue-growth BiopharmaWatch en 2026-08-14T12:08:00.000Z SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-14T12:00:09.000Z PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights https://www.biopharmawatch.com/news/LNTH/lantheus-fda-approval-tauclarify-alzheimers-imaging BiopharmaWatch en 2026-08-14T12:00:00.000Z Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease https://www.biopharmawatch.com/news/PAVM/pavmed-business-update-q2-2026-results BiopharmaWatch en 2026-08-14T12:00:00.000Z PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-14T12:00:00.000Z Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update https://www.biopharmawatch.com/news/REPL/replimune-fiscal-q1-2027-results-update BiopharmaWatch en 2026-08-14T12:00:00.000Z Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ANVS/annovis-corporate-updates-q2-2026-results BiopharmaWatch en 2026-08-14T12:00:00.000Z Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-phase-3-ready-stenoparib-results BiopharmaWatch en 2026-08-14T12:00:00.000Z Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign https://www.biopharmawatch.com/news/EVAX/evaxion-business-update-q2-2026-results BiopharmaWatch en 2026-08-14T12:00:00.000Z Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026 https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-14T12:00:00.000Z Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/GTBP/gt-biopharma-q2-2026-financial-results BiopharmaWatch en 2026-08-14T12:00:00.000Z GT Biopharma Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-q2-2026-financial-results-update BiopharmaWatch en 2026-08-14T11:45:00.000Z TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-executive-team-appointments BiopharmaWatch en 2026-08-14T11:30:00.000Z Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments https://www.biopharmawatch.com/news/LTRN/lantern-pharma-q2-2026-financial-results BiopharmaWatch en 2026-08-14T11:30:00.000Z Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/USPH/us-physical-therapy-announces-cfo BiopharmaWatch en 2026-08-14T11:30:00.000Z U.S. Physical Therapy Announces CFO https://www.biopharmawatch.com/news/CGC/canopy-growth-renewed-eu-gmp-certification-kincardine BiopharmaWatch en 2026-08-14T11:30:00.000Z Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-secondary-offering-pricing BiopharmaWatch en 2026-08-14T11:30:00.000Z BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base https://www.biopharmawatch.com/news/MLSS/milestone-scientific-q2-2026-financial-results BiopharmaWatch en 2026-08-14T11:30:00.000Z Milestone Scientific Reports Financial Results for Second Quarter 2026 https://www.biopharmawatch.com/news/HELP/helus-pharma-q1-fiscal-2027-results BiopharmaWatch en 2026-08-14T11:28:46.000Z Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-approval-lytenava-business-update BiopharmaWatch en 2026-08-14T11:15:00.000Z Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-08-14T11:01:00.000Z Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update https://www.biopharmawatch.com/news/ANL/adlai-nortye-first-half-2026-financial-results BiopharmaWatch en 2026-08-14T11:00:00.000Z Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-14T11:00:00.000Z Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-q2-2026-results-business-update BiopharmaWatch en 2026-08-14T11:00:00.000Z Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reclaim-ln-clinical-trial-ft819-lupus-nephritis BiopharmaWatch en 2026-08-14T11:00:00.000Z Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-14T10:44:00.000Z Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/IPHA/innate-pharma-conference-call-webcast BiopharmaWatch en 2026-08-14T09:30:00.000Z Innate Pharma Announces Conference Call and Webcast https://www.biopharmawatch.com/news/PFE/pfizer-valneva-lyme-disease-vaccine-ema-validation BiopharmaWatch en 2026-08-14T05:00:00.000Z Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-public-offering-pricing BiopharmaWatch en 2026-08-14T02:23:00.000Z Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering